Korlym (mifepristone)
Effective 10/01/2020

<table>
<thead>
<tr>
<th>Plan</th>
<th>Benefit</th>
<th>Program Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>☒ MassHealth</td>
<td>☒ Pharmacy Benefit</td>
<td>☒ Prior Authorization</td>
</tr>
<tr>
<td>☒ Commercial/Exchange</td>
<td>☐ Medical Benefit (NLX)</td>
<td>☐ Quantity Limit</td>
</tr>
<tr>
<td>☒ Prior Authorization</td>
<td></td>
<td>☐ Step Therapy</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Specialty Limitations</th>
<th>Specialty Medications</th>
<th>Non-Specialty Medications</th>
<th>Medical Specialty Medications (NLX)</th>
</tr>
</thead>
<tbody>
<tr>
<td>N/A</td>
<td>All Plans Phone: 866-814-5506 Fax: 866-249-6155</td>
<td>MassHealth Phone: 877-433-7643 Fax: 866-255-7569</td>
<td>All Plans Phone: 844-345-2803 Fax: 844-851-0882</td>
</tr>
<tr>
<td></td>
<td>Commercial Phone: 800-294-5979 Fax: 888-836-0730</td>
<td>Commercial Phone: 855-582-2022 Fax: 855-245-2134</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Exchange Phone: 855-582-2022 Fax: 855-245-2134</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exceptions</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Overview
Korlym (mifepristone) is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.

Coverage Guidelines
Authorization may be granted for members who are currently receiving treatment with Korlym, excluding when the product is obtained as samples or via manufacturer’s patient assistance programs

OR
Authorization may be granted if the member meets all following criteria and documentation has been submitted:
1. The member is diagnosed hyperglycemia secondary to hypercortisolism with endogenous Cushing syndrome who have type 2 diabetes mellitus or glucose intolerance
2. The member is ≥ 18 years of age
3. The member has had an inadequate response or adverse reaction to one or contraindication to both of the following: ketoconazole tablets, Lysodren tablets.
4. The member has failed surgical intervention (recurrence after surgery or failed tumor removal)

OR
5. Surgical interventions are not appropriate.

Continuation of Therapy
Reauthorization requires clinical documentation of clinical response.

Limitations
1. Initial approvals will be issued for 6 months

399 Revolution Drive, Suite 810, Somerville, MA 02145 | allwayshealthpartners.org
2. Reauthorization will be issued for 12 months
3. The following quantity limits apply:

| Korlym 300mg | 120 tablets per 30 days |

References
1. Korlym (mifepristone) [prescribing information]. Menlo Park, CA: Corcept Therapeutics; November 2019

Review History
2014 - Implemented
9/23/13 – Reviewed
9/22/14 – Reviewed
9/21/15 – Reviewed
9/19/16 – Reviewed
9/18/17 – Reviewed
9/24/18 – Reviewed
9/18/19 – Reviewed
7/22/20 – Reviewed and Updated July P&T Mtg; Updated Program Type to PA and QL. Effective 10/01/2020
9/16/20 – Reviewed at September P&T; Updated references.
9/22/2021 – Reviewed at P&T; no clinical changes

Disclaimer
AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.